Compare Anheuser-Busch Inbev SA (BUD) vs Centene Corp (CNC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Anheuser-Busch Inbev SA vs Centene Corp — how do they compare? Anheuser-Busch Inbev SA trades at $79.37 (market cap $153.45B), while Centene Corp trades at $66.5 (market cap $33.93B). The key difference: Anheuser-Busch Inbev SA is far larger — about 4.5× Centene Corp's market cap, and Anheuser-Busch Inbev SA pays a 1.7% dividend while Centene Corp pays none. Which is the better fit depends on your goals.
| BUD | CNC | |
|---|---|---|
Market Cap | $153.45B | $33.93B |
Sector | Consumer Staples | Health |
52-Week High | $85.09 | $68.72 |
52-Week Low | $57.10 | $25.21 |
Enterprise Value | $214.64B | $26.56B |
Dividend Yield | 1.7% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BUD trades at $79.33, down 0.35% with bearish technical signals. The company demonstrates solid fundamentals with consistent earnings beats, 11.9% net margin, and improving cash flow. Recent dividend payment of $1.17 and positive analyst sentiment with 57.8% buy ratings support the investment case. Premiumization strategy and digital expansion drive growth amid changing consumer preferences.
Outlook remains positive with $90.08 consensus price target offering 13.5% upside. Key risks include alcohol moderation trends and competitive pressures. Strong balance sheet with declining debt-to-asset ratio to 33.9% provides financial stability. Revenue growth expected to accelerate to $61B in 2026 with expanding margins.
Centene Corporation (CNC) trades at $68.29, up 1.4% with strong technical momentum and bullish moving average signals. The stock shows impressive 66% YTD gains, supported by recent contract renewals and margin recovery initiatives. Despite negative 2025 net income of -$6.67B, valuation metrics remain attractive with P/E of 8.06 and P/S of 0.17. Analyst consensus is strongly bullish with 61% buy ratings and $66.07 price target.
Centene presents a compelling value opportunity with low valuation multiples and strong operational cash flow of $5.09B. Key risks include ongoing margin pressure and Medicaid contract dependency. The company's AI-driven cost controls and recent Illinois Medicaid renewal provide catalysts for earnings recovery, though healthcare regulatory changes remain a concern for long-term stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Anheuser-Busch Inbev SA
Anheuser-Busch InBev is the largest brewer in the world and one of the world's top five consumer product companies, as measured by EBITDA. After the SABMiller acquisition, the company's portfolio now contains five of the top 10 beer brands by sales and 18 brands with retail sales over $1 billion. AB InBev was created by the 2008 merger of Belgium-based InBev and U.S.-based Anheuser-Busch. The firm holds a 62% economic interest in Ambev and in 2016 acquired SABMiller.
Read more on BUD →About Centene Corp
Centene is a managed-care organization focused on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 22 million medical members as of September 2021, mostly in Medicaid (68% of membership), the individual exchanges (10%), Medicare Advantage (6%), and the balance in Tricare (West region), correctional facility, and international plans. The company also serves 4 million users through the Medicare Part D pharmaceutical program.
Read more on CNC →
